Trokendi XR, 25mg recall — Supernus Pharmaceuticals, Inc. (Unclassified)

Supernus Pharmaceuticals, Inc. is recorded by the U.S. Food and Drug Administration (FDA) as recalling Trokendi XR, 25mg — an Unclassified recall, initiated 2026-07-06 and posted to the FDA enforcement report on 2026-07-29, for which the source publishes no recall number. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Failed Dissolution Specifications”. From the product description, the form is extended-release capsules, the strength given is 25mg, the package is described as 30 Capsules and it is marked Rx only. 1 National Drug Code number is printed in the record: 17772-101-30. Distribution is recorded as “US Nationwide” — Nationwide (US), with the recalling firm on record in MD, United States. It is the only recall number the FDA has filed under event ID 99375. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.

Regulatory snapshot

Recall number N/A — the source publishes no recall number for this record
FDA event ID 99375
Classification Unclassified
Status Ongoing
Recalling firm Supernus Pharmaceuticals, Inc.
Recall initiated 2026-07-06
Reported by FDA 2026-07-29
Report lag 23 days from initiation to report
Distribution US Nationwide. — Nationwide (US)
Firm location on record MD, United States
Product description (source) Trokendi XR, topiramate extended-release capsules, 25mg, 30 Capsules, Rx only, Manufactured by: Catalent Pharma Solutions, Winchester, KY 40391 USA, Manufactured for: Supernus Pharmaceuticals, Inc., Rockville, MD 20850 USA, NDC 17772-101-30.

Reason reported by FDA

Failed Dissolution Specifications

3 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.

Product identifiers in this record

7 identifying values matched by exact pattern in the 30-word product description above; each is a literal substring of it.

Product named Trokendi XR
Form Extended-Release Capsules
Strength 25mg
Package 30 Capsules
NDC 17772-101-30
Marketing category Rx only
Manufactured by Catalent Pharma Solutions, Winchester
Manufactured for Supernus Pharmaceuticals, Inc.

Reported in the same month (2026-07)

111 enforcement reports carry a report date in 2026-07; these 16 are the Unclassified ones nearest this record.

Recall recordRecall numberRecalling firmFDA tierReported
Levothyroxine Sodium Tablets, 25 mcgD-0700-2026Major PharmaceuticalsClass II2026-07-29
Levothyroxine Sodium Tablets, 50 mcgD-0701-2026Major PharmaceuticalsClass II2026-07-29
Levothyroxine Sodium Tablets, 75 mcgD-0702-2026Major PharmaceuticalsClass II2026-07-29
Levothyroxine Sodium Tablets, 88 mcgD-0703-2026Major PharmaceuticalsClass II2026-07-29
Levothyroxine Sodium Tablets, 112 mcgD-0704-2026Major PharmaceuticalsClass II2026-07-29
Levothyroxine Sodium Tablets, 125 mcgD-0705-2026Major PharmaceuticalsClass II2026-07-29
Levothyroxine Sodium Tablets, 150 mcgD-0706-2026Major PharmaceuticalsClass II2026-07-29
Levothyroxine Sodium Tablets, 25 mcgD-0707-2026Major PharmaceuticalsClass II2026-07-29
Levothyroxine Sodium Tablets, 50 mcgD-0708-2026Major PharmaceuticalsClass II2026-07-29
Levothyroxine Sodium Tablets, 75 mcgD-0709-2026Major PharmaceuticalsClass II2026-07-29
Levothyroxine Sodium Tablets, 125 mcgD-0710-2026Major PharmaceuticalsClass II2026-07-29
Levothyroxine Sodium Tablets, 150 mcgD-0711-2026Major PharmaceuticalsClass II2026-07-29
Amlodipine and Olmesartan Medoxomil Tablets, 10 mg/20 mgD-0712-2026Ascend Laboratories, LLCClass II2026-07-29
Lidolog Kit, 2%D-0713-2026Asclemed Usa Inc.Class III2026-07-29
Rohto Cooling Eye Drops ALL-IN-ONE, 0.2%D-0715-2026Rohto-mentholatum (vietnam) Co., Ltd.Class II2026-07-29
Rohto Cooling Eye Drops Max Strength, 0.03%D-0716-2026Rohto-mentholatum (vietnam) Co., Ltd.Class II2026-07-29

Reading this record

Unclassified is the FDA's own severity tier for the recall action — 1 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. Match a package against 17772-101-30 at the FDA source to confirm it is covered.

Namespace context: the Unclassified index (1 records) and the recall hub (250 records, 118 FDA events); Supernus Pharmaceuticals, Inc. (1 indexed records) aggregates this firm across datasets.

Coverage and limits of this record

This page reflects the openFDA enforcement report for this recall as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.

Source & provenance

Official source
https://api.fda.gov/drug/enforcement.json?search=recall_number:%22N%2FA%22
Source dataset
openFDA Drug Enforcement API
Publication date
2026-07-29
Ingested
2026-08-22
Record hash
3f7734662a6f0e43

Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.